Neos Therapeutics Inc  

(Public, NASDAQ:NEOS)   Watch this stock  
Find more results for Neos Therapeutics, Inc.�
20.01
+0.45 (2.30%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.40 - 20.80
52 week 17.10 - 21.86
Open 19.51
Vol / Avg. 33,733.00/683,523.00
Mkt cap 289.92M
P/E     -
Div/yield     -
EPS -1.88
Shares 13.69M
Beta     -
Inst. own 0%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1531.78% -2750.53%
Operating margin -1553.74% -2436.94%
EBITD margin - -2079.02%
Return on average assets -52.67% -47.87%
Return on average equity - -
CDP Score - -

Address

2940 N State Highway 360 Ste 400
GRAND PRAIRIE, TX 75050-6424
United States - Map
+1-972-4081360 (Phone)
+1-972-4081143 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Neos Therapeutics, Inc. is a pharmaceutical company that is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company's product candidates incorporate two prescribed medications for the treatment of attention deficit hyperactivity disorder (ADHD), methylphenidate and amphetamine. Its product candidates are extended-release (XR), medications in orally disintegrating tablets (ODT), as well as liquid suspension dosage forms. The Company's portfolio of products includes NT-0102, NT-0202, NT-0201 and Generic Tussionex. NT-0102 is an amphetamine XR-ODT used for the treatment of ADHD. NT-0201 is an amphetamine XR Liquid Suspension used for the treatment of ADHD. The Company manufactures and markets a generic equivalent to the branded product, Tussionex.

Officers and directors

Alan Heller Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Vipin K. Garg Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Richard Eisenstadt Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Mark Tengler Chief Technology Officer
Age: 47
Bio & Compensation  - Reuters
Dorothy Engelking Vice President of Regulatory Affairs
Age: 54
Bio & Compensation  - Reuters
Thomas P McDonnell Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Caley Castelein M.D. Non-Executive Director
Age: 44
Bio & Compensation  - Reuters
Paul R. Edick Non-Executive Director
Age: 60
Bio & Compensation  - Reuters
Bryant Fong Non-Executive Director
Age: 42
Bio & Compensation  - Reuters
Gregory J. Robitaille Non-Executive Director
Bio & Compensation  - Reuters